July 25, 2017 | SOURCE: PR NEWSWIRE

Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators
Novel Activators Demonstrate Selective Inhibition of IL-17a and IL-2